Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on on healthcare or medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine. For up-to-date information on other healthcare topics, please consult the relevant reliable sources or an healthcare expert, such as a physician etc.
 BACK TO LIST

Laboratory Report

Patient
Name: Roberts, Carly
DOB: 10-DEC-1969 (Age: 56)
Gender: female
Address:
2 Price meadow
LE4 Mitchellborough (United Kingdom)
ID: 9384-259853-9 (ECI)
Report
Date: 13-NOV-2024
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
St Matthews Health & Community Centre
Malabar Road 62-66
LE1 4 Leicester (United Kingdom)
Specimen
Collected: 13-NOV-2024

Hematology

Test 13-NOV-2024 Reference Range Unit
Leukocytes [#/volume] in Blood by Automated count 10.6 4.0 - 11.0 10*3/uL
Erythrocytes [#/volume] in Blood by Automated count 3.9 L 4.2 - 5.4 10*6/uL
Hemoglobin [Mass/volume] in Blood 17.3 H 12 - 16 g/dL
Hematocrit [Volume Fraction] of Blood by Automated count 36.9 36 - 46 %
MCV [Entitic mean volume] in Red Blood Cells by Automated count 87.7 80 - 100 fL
MCH [Entitic mass] by Automated count 27.0 27 - 33 pg
MCHC [Entitic Mass/volume] in Red Blood Cells by Automated count 35.5 32 - 36 g/dL
Erythrocyte [DistWidth] in Blood by Automated count 13.8 11.5 - 14.5 %
Platelets [#/volume] in Blood by Automated count 213.4 150 - 450 10*3/uL

Chemistry

Test 13-NOV-2024 Reference Range Unit
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 1661.0 H 0 - 450 pg/mL
Glucose [Mass/volume] in Serum or Plasma 94.0 65 - 99 mg/dL
Urea nitrogen [Mass/volume] in Serum or Plasma 16.6 7 - 20 mg/dL
Creatinine [Mass/volume] in Serum or Plasma 0.8 0.5 - 1.1 mg/dL
Calcium [Mass/volume] in Serum or Plasma 9.1 8.6 - 10.3 mg/dL
Sodium [Moles/volume] in Serum or Plasma 142.8 135 - 145 mmol/L
Potassium [Moles/volume] in Serum or Plasma 3.8 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Serum or Plasma 109.5 98 - 110 mmol/L
Carbon dioxide, total [Moles/volume] in Serum or Plasma 26.8 22 - 32 mmol/L
Protein [Mass/volume] in Serum or Plasma 7.8 6.6 - 8.3 g/dL
Albumin [Mass/volume] in Serum or Plasma 4.8 3.5 - 5.2 g/dL
Bilirubin.total [Mass/volume] in Serum or Plasma 0.8 0.1 - 1.2 mg/dL
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 102.3 H 32 - 91 U/L
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 30.5 7 - 56 U/L
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 37.5 10 - 40 U/L
Magnesium [Mass/volume] in Serum or Plasma 1.8 1.7 - 2.2 mg/dL
Cholesterol [Mass/volume] in Serum or Plasma 128.0 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 115.9 0 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 72.2 0 - 100 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 32.6 L 40 - 60 mg/dL
Hemoglobin A1c/Hemoglobin.total in Blood 5.0 4.0 - 5.6 %
Troponin I.cardiac [Mass/volume] in Serum or Plasma by High sensitivity method 0.0 0.0 - 19.9 pg/mL
Ferritin [Mass/volume] in Serum or Plasma 34.1 13 - 150 ug/L
Iron [Mass/volume] in Serum or Plasma 37.9 L 50 - 170 ug/dL
Iron binding capacity [Mass/volume] in Serum or Plasma 439.1 250 - 450 ug/dL
Iron saturation [Mass Fraction] in Serum or Plasma 22.5 15 - 50 %

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient shows markedly elevated NT-proBNP, suggesting possible heart failure or significant cardiac stress. There is mild erythrocytopenia with high hemoglobin, possibly due to hemoconcentration. Alkaline phosphatase is slightly elevated, which may indicate mild hepatobiliary or bone involvement. Iron and HDL cholesterol are low, suggesting possible iron deficiency and increased cardiovascular risk. Other parameters are within normal limits. Clinical correlation and further evaluation are recommended.